PDUFA VII Talks To Begin With COVID-19, Other Familiar Issues To Consider
Executive Summary
US FDA staffing problems and patient engagement enhancements will be listed as priorities during reauthorization kick-off meeting.
You may also be interested in...
A More Perfect Meeting: Industry Seeks Additional PDUFA VII Metrics To Improve Communications
Will the US FDA agree to more structured communications amid its struggles with the existing meeting workload?
US FDA, Industry Share Early Lessons From Complex Innovative Trial Designs Program
Timelines in the CID program are tight, and sponsors should have a ‘fully baked’ trial design before heading into their first meeting with the agency, industry reps say; agency needs more simulation data from participating sponsors earlier and is working to ensure continuity for firms after the second of two meetings allowed under the program.
US FDA’s Data Strategy Under Increasing Pressure From Coronavirus Pandemic
As agency prepares to hear from stakeholders on its strategy, real-world data precedents already are being set thanks to COVID-19, Aetion tells the Pink Sheet.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available Buy Reports
Need a specific report? 1000+ reports available Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: